Bracco Imaging, a global leader in diagnostic imaging, completed the acquisition of Blue Earth Diagnostics, a molecular imaging company based in Oxford, UK. Bracco Imaging will acquire all outstanding shares of privately-held Blue Earth Diagnostics for the equity value of $450m, plus closing adjustment estimated at $25m, from leading healthcare company Syncona and Blue Earth Diagnostics’ management team. “Blue Earth Diagnostics’ innovative products and pipeline will significantly enhance Bracco Imaging’s portfolio in precision medicine and personalized diagnostics, while expanding our range of nuclear oncology imaging solutions in the Urology segment and other specialties. We are thrilled to welcome to Bracco this world class team with exceptional product development and commercialization expertise,” Fulvio Renoldi Bracco, Bracco Imaging CEO.